A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 Plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral Regimen of GSK1265744 Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Cabotegravir+rilpivirine (Primary) ; Lamivudine/abacavir (Primary) ; Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms LATTE 2
- Sponsors ViiV Healthcare
- 17 May 2023 Status changed from active, no longer recruiting to completed.
- 04 Oct 2022 Planned End Date changed from 30 Dec 2022 to 28 Apr 2023.
- 02 Jun 2022 This trial has been completed in Germany, according to European Clinical Trials Database record.